|
Gene: SLC38A11 |
Gene summary for SLC38A11 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC38A11 | Gene ID | 151258 |
Gene name | solute carrier family 38 member 11 | |
Gene Alias | AVT2 | |
Cytomap | 2q24.3 | |
Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | Q08AI6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
151258 | SLC38A11 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.96e-35 | 7.12e-01 | 0.3005 |
151258 | SLC38A11 | CRC-1-8810 | Human | Colorectum | CRC | 1.40e-59 | 1.18e+00 | 0.6257 |
151258 | SLC38A11 | HCC1_Meng | Human | Liver | HCC | 1.68e-03 | -1.05e-01 | 0.0246 |
151258 | SLC38A11 | HCC2 | Human | Liver | HCC | 9.53e-11 | 1.23e-01 | 0.5341 |
151258 | SLC38A11 | S014 | Human | Liver | HCC | 6.29e-04 | 5.45e-01 | 0.2254 |
151258 | SLC38A11 | S016 | Human | Liver | HCC | 5.14e-12 | 6.80e-01 | 0.2243 |
151258 | SLC38A11 | HTA12-23-1 | Human | Pancreas | PDAC | 8.00e-12 | 8.81e-01 | 0.3405 |
151258 | SLC38A11 | HTA12-25-1 | Human | Pancreas | PDAC | 3.52e-06 | 5.06e-01 | 0.313 |
151258 | SLC38A11 | HTA12-26-1 | Human | Pancreas | PDAC | 4.88e-07 | 4.28e-01 | 0.3728 |
151258 | SLC38A11 | HTA12-29-1 | Human | Pancreas | PDAC | 6.38e-18 | 5.05e-01 | 0.3722 |
151258 | SLC38A11 | HTA12-32-1 | Human | Pancreas | PDAC | 1.46e-03 | 8.99e-01 | 0.3624 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00068141 | Colorectum | CRC | sodium ion transport | 49/2078 | 245/18723 | 3.01e-05 | 7.86e-04 | 49 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC38A11 | SNV | Missense_Mutation | c.354N>G | p.Ile118Met | p.I118M | Q08AI6 | protein_coding | tolerated(0.09) | benign(0.423) | TCGA-BS-A0TE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
SLC38A11 | SNV | Missense_Mutation | novel | c.607T>C | p.Ser203Pro | p.S203P | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC38A11 | SNV | Missense_Mutation | novel | c.1017N>T | p.Lys339Asn | p.K339N | Q08AI6 | protein_coding | tolerated(0.25) | benign(0.327) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SLC38A11 | SNV | Missense_Mutation | novel | c.284T>G | p.Ile95Ser | p.I95S | Q08AI6 | protein_coding | tolerated(0.34) | benign(0.007) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLC38A11 | SNV | Missense_Mutation | novel | c.331C>T | p.Pro111Ser | p.P111S | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SLC38A11 | SNV | Missense_Mutation | novel | c.34C>A | p.Leu12Ile | p.L12I | Q08AI6 | protein_coding | tolerated(0.06) | possibly_damaging(0.872) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SLC38A11 | SNV | Missense_Mutation | novel | c.425N>A | p.Arg142Lys | p.R142K | Q08AI6 | protein_coding | tolerated(0.1) | possibly_damaging(0.836) | TCGA-DD-AACQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
SLC38A11 | SNV | Missense_Mutation | novel | c.857N>A | p.Val286Glu | p.V286E | Q08AI6 | protein_coding | deleterious(0) | possibly_damaging(0.694) | TCGA-64-5781-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SLC38A11 | SNV | Missense_Mutation | c.290N>A | p.Arg97His | p.R97H | Q08AI6 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-73-4670-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
SLC38A11 | SNV | Missense_Mutation | novel | c.331N>T | p.Pro111Ser | p.P111S | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |